Trump administration attacks on the National Institutes of Health mean biomedical research will become less ambitious, less ...
CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -- Flexible Dosing and Extended Duration would be Important ...
Clearside Biomedical (CLSD) announced the receipt of the formal meeting minutes from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration relating to CLS-AX for the ...
March 06, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical ... Phase 3 program during our upcoming earnings call later this month.” Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of ...